Get the Stockscreener App
1.12
0.88%
-0.010
Clearmind Medicine Inc stock is traded at $1.12, with a volume of 4,012.
It is down -0.88% in the last 24 hours and down -20.57% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
4,012
Relative Volume:
0.00
Market Cap:
$5.30M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0262
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
+5.66%
1M Performance:
-20.57%
6M Performance:
-16.42%
1Y Performance:
-6.67%
1-Day Range:
$1.13
$1.13
1-Week Range:
$1.05
$1.16
52-Week Range:
$0.9512
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.13 | 5.30M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.89 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.22 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.90 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.85 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.39 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine (CMND) versus Its Peers Head to Head Contrast - Defense World
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves - Financial Content
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
Clearmind secures South Korean patent for addiction therapy By Investing.com - Investing.com South Africa
Clearmind secures South Korean patent for addiction therapy - Investing.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - StockTitan
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Cocaine Addiction - Nasdaq
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
Obesity Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Head-To-Head Comparison: Clearmind Medicine (CMND) versus The Competition - Defense World
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
Clearmind Medicine Secures Patent For Psychedelic Combination Therapy In Mexico - Nasdaq
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Innovative Combination Therapy Targeting Binge Behavior - Nasdaq
Novel Psychedelic-Based Therapy Gets Patent Green Light: Targets Multiple Addictions - StockTitan
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Trading Up 6.3% – Still a Buy? - Defense World
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Clearmind Medicine Announces Shareholders Meeting Results - The Manila Times
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Clearmind Medicine files European patent for binge behavior therapy By Investing.com - Investing.com Nigeria
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
Clearmind Medicine files European patent for binge behavior therapy - Investing.com
Lexitas Elevates Nishat Mehta to CEO, Prepares to Launch AI-Assisted Solutions for the Legal Profession Throughout 2025 - The Manila Times
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - The Manila Times
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - GlobeNewswire Inc.
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
Clearmind Medicine to move forward with MEAI-based alcohol substitute - Yahoo Finance
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - EIN News
Clearmind Medicine Partners with Dr Glitter to Develop Crystal-Based Alcohol Alternative - StockTitan
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 - MSN
Clearmind Medicine advances in AUD treatment trial By Investing.com - Investing.com South Africa
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):